Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing from NanoMab
Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing from NanoMab
NanoMab believes the strategic collaborations between the respective parties will expedite development of NM-01 and ensure its diagnostic and therapeutic potential can soon benefit patients in the battle against PD-L1 expressing malignancies.
